MP14-02 PROSPECTIVE QUALITY OF LIFE IMPACT ANALYSIS FOLLOWING LOCALIZED PROSTATE CANCER TREATMENTS: BRACHYTHERAPY, CRYOTHERAPY, AND RADICAL PROSTATECTOMY LONG-TERM FOLLOW-UP

Abstract

You have accessJournal of UrologyProstate Cancer: Epidemiology & Natural History III1 Apr 2015MP14-02 PROSPECTIVE QUALITY OF LIFE IMPACT ANALYSIS FOLLOWING LOCALIZED PROSTATE CANCER TREATMENTS: BRACHYTHERAPY, CRYOTHERAPY, AND RADICAL PROSTATECTOMY LONG-TERM FOLLOW-UP Matthew Ingham, Arjun Poddar, Mark Shaves, Michael Fabrizio, Raymond Lance, Robert Given, Kurt McCammon, Paul Schellhammer, and Michael Williams Matthew InghamMatthew Ingham More articles by this author , Arjun PoddarArjun Poddar More articles by this author , Mark ShavesMark Shaves More articles by this author , Michael FabrizioMichael Fabrizio More articles by this author , Raymond LanceRaymond Lance More articles by this author , Robert GivenRobert Given More articles by this author , Kurt McCammonKurt McCammon More articles by this author , Paul SchellhammerPaul Schellhammer More articles by this author , and Michael WilliamsMichael Williams More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.864AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES A number of treatment modalities for localized prostate cancer (CaP) exist, often with similar oncologic outcomes. As such, health related quality of life (HRQOL) plays a significant role in treatment decisions. We sought to evaluate the long-term HRQOL impact of four such treatments. METHODS Patients undergoing open radical prostatectomy (ORP), robotic assisted prostatectomy (RAP), brachytherapy (BT), or cryotherapy (CRYO) for localized CaP between March 2002 and October 2009 were asked to complete the UCLA-PCI pre-op and at 1, 3, 6, 12, 18, 24, 30, 36, 48, and 60 months post-op. 586 of 1094 patients returned surveys out to the 60-month endpoint. Outcomes were compared across treatment modalities and age cohorts (<60, 60–70, and >70 years). Baseline scores were obtained along with a percent of baseline score (PBS) for all subsequent surveys. RESULTS For urinary function (UF) and bother (UB) domains, those undergoing BT or CRYO showed a significant improvement in HRQOL vs ORP or RAP, which persisted to the 60-month endpoint. BT and CRYO also showed a faster return of HRQOL, plateauing by 6–12 months compared with ORP and RAP which plateaued at 18–24 months (Fig 1). Sexual function (SF) and bother (SB) domains showed a significantly improved HRQOL for BT over ORP, RAP, and CRYO. By 12 months, BT patients had roughly double the improvement of the other groups. BT, however, demonstrated a decline in SF after 36 months vs ORP, RAP, and CRYO which had stable SF over the same period. For patients > 70 years, a near complete return to baseline UF and UB by 12 months was noted which persisted to 60 months vs the younger cohorts whose PBS plateaued at roughly 80. Conversely, at 60 months, SF PBS scores of 53, 41, and 29 were found for the <60, 60–70, and >70 years cohorts, respectively. CONCLUSIONS In this cohort of patients followed to 5 years, BT and CRYO offer durable HRQOL benefits in both UF and UB over ORP and RAP. BT alone offers improved HRQOL outcomes for SF as compared to ORP, RAP, or CRYO. Patients age >70 have an excellent recovery of baseline UF and UB but do poorly with SF recovery as compared to younger cohorts. Certainly, these findings can be employed for appropriate counselling prior to treatment decisions. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e151 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Matthew Ingham More articles by this author Arjun Poddar More articles by this author Mark Shaves More articles by this author Michael Fabrizio More articles by this author Raymond Lance More articles by this author Robert Given More articles by this author Kurt McCammon More articles by this author Paul Schellhammer More articles by this author Michael Williams More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...